---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-25-005427"
form_type: "8-K"
ticker: "BNGO"
cik: "0001411690"
company_name: "Bionano Genomics, Inc."
filed_at: "2025-02-21T23:59:59+00:00"
generated_at: "2026-05-26T06:53:33.639689+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Bionano Genomics enters new $75M ATM sales agreement with H.C. Wainwright, replacing Cowen facility

## Summary
- Terminated prior Cowen sales agreement effective Feb 14, 2025; suspended offering Feb 4.
- New ATM with H.C. Wainwright allows sale of up to $75M of common stock at market prices.
- Wainwright receives 3.0% commission on gross proceeds from each sale.
- Shares sold on Nasdaq through at-the-market offerings; company may suspend at any time.
- Registration statement on Form S-3 effective May 10, 2023, covering the new facility.

## SEC filing metadata
- accession: 0001140361-25-005427
- form_type: 8-K
- ticker: BNGO
- cik: 0001411690
- company_name: Bionano Genomics, Inc.
- filed_at: 2025-02-21T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1411690/000114036125005427/0001140361-25-005427-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1411690/000114036125005427/ef20043949_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-25-005427
- JSON: https://secwatch.observer/filing/0001140361-25-005427.json
- Plain text: https://secwatch.observer/filing/0001140361-25-005427.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.